Lise I. Loberg

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

Glenwood Goss, Everett E. Vokes, Michael S. Gordon et al. · Cancer · 2018 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya et al. · Molecular Cancer Therapeutics · 2018 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment

Michael W. Leach, David O. Clarke, Sherri Dudal et al. · Clinical Pharmacology & Therapeutics · 2020 · 33 citations

Medicine, Pharmacology, Biopharmaceutics +16

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

Fiona Sewell, Kathryn Chapman, Jessica A. Couch et al. · mAbs · 2017 · 30 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Gene expression in human breast epithelial cells exposed to 60 Hz magnetic fields

Lise I. Loberg · Carcinogenesis · 1999 · 28 citations

Medicine, Cancer Biology, Molecular Biology +13